Oklo stock tumbles as Financial Times scrutinizes valuation
GSK plc (LSE/NYSE:GSK) and Alector, Inc. (NASDAQ:ALEC) announced Tuesday that they will discontinue further studies of latozinemab in frontotemporal dementia associated with progranulin gene mutation (FTD-GRN), following results from the INFRONT-3 clinical trial.
According to a statement released Monday and filed with the U.S. Securities and Exchange Commission, the trial met its biomarker co-primary endpoint, showing a statistically significant increase in plasma progranulin concentrations among participants treated with latozinemab. However, the drug did not demonstrate benefit on the clinical co-primary endpoint of slowing progression of FTD-GRN. Secondary and exploratory endpoints also showed no treatment-related effects.
Preliminary safety data from the trial did not identify any major safety concerns. GSK stated that more detailed analysis of the data is ongoing.
As a result of these findings, the companies will discontinue the open-label extension portion of the INFRONT-3 trial and the continuation study for latozinemab.
GSK and Alector began their collaboration in July 2021 to develop and commercialize monoclonal antibodies that elevate progranulin, including latozinemab. Alector led the early clinical development, with both companies sharing responsibilities and costs for later-stage trials.
GSK stated that full results from the INFRONT-3 study will be presented at an upcoming medical congress. The company also indicated it will review the complete data set to inform future research decisions.
This information is based on a press release statement filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.